NGM Biopharmaceuticals In... (NGM)
NGM Biopharmaceuticals Statistics
Share Statistics
NGM Biopharmaceuticals has 83.46M shares outstanding. The number of shares has increased by 0% in one year.
| Shares Outstanding | 83.46M |
| Shares Change (YoY) | 0% |
| Shares Change (QoQ) | 0% |
| Owned by Institutions (%) | n/a |
| Shares Floating | 28.89M |
| Failed to Deliver (FTD) Shares | 3.37K |
| FTD / Avg. Volume | 0.31% |
Short Selling Information
| Short Interest | n/a |
| Short % of Shares Out | n/a |
| Short % of Float | n/a |
| Short Ratio (days to cover) | n/a |
Valuation Ratios
The PE ratio is -0.5 and the forward PE ratio is null. NGM Biopharmaceuticals's PEG ratio is 0.04.
| PE Ratio | -0.5 |
| Forward PE | n/a |
| PS Ratio | 16.04 |
| Forward PS | null |
| PB Ratio | 0.48 |
| P/FCF Ratio | -0.53 |
| PEG Ratio | 0.04 |
Enterprise Valuation
NGM Biopharmaceuticals has an Enterprise Value (EV) of 12.05M.
| EV / Sales | 2.73 |
| EV / EBITDA | -0.08 |
| EV / EBIT | -0.09 |
| EV / FCF | -0.09 |
Financial Position
The company has a current ratio of 7.79, with a Debt / Equity ratio of 0.
| Current Ratio | 7.79 |
| Quick Ratio | 7.79 |
| Debt / Equity | 0 |
| Debt / EBITDA | 0 |
| Debt / FCF | 0 |
| Interest Coverage | 0 |
Financial Efficiency
Return on Equity is -95.79% and Return on Invested Capital is -98.59%.
| Return on Equity | -95.79% |
| Return on Assets | -84.31% |
| Return on Invested Capital | -98.59% |
| Revenue Per Employee | $32.01K |
| Profits Per Employee | $-1.03M |
| Employee Count | 138 |
| Asset Turnover | 0.03 |
| Inventory Turnover | n/a |
Taxes
| Income Tax | 0 |
| Effective Tax Rate | 0% |
Stock Price Statistics
The stock price has increased by 0% in the last 52 weeks. The beta is 1.26, so NGM Biopharmaceuticals's price volatility has been higher than the market average.
| Beta | 1.26 |
| 52-Week Price Change | 0% |
| 50-Day Moving Average | 1.55 |
| 200-Day Moving Average | 1.52 |
| Relative Strength Index (RSI) | 48.53 |
| Average Volume (20 Days) | 1.07M |
Income Statement
In the last 12 months, NGM Biopharmaceuticals had revenue of 4.42M and earned -142.38M in profits. Earnings per share was -1.73.
| Revenue | 4.42M |
| Gross Profit | 2.2M |
| Operating Income | -146.55M |
| Net Income | -142.38M |
| EBITDA | -144.33M |
| EBIT | n/a |
| Earnings Per Share (EPS) | -1.73 |
Balance Sheet
The company has 58.81M in cash and 0 in debt, giving a net cash position of 58.81M.
| Cash & Cash Equivalents | 58.81M |
| Total Debt | 0 |
| Net Cash | 58.81M |
| Retained Earnings | -724.01M |
| Total Assets | 168.87M |
| Working Capital | 136.36M |
Cash Flow
In the last 12 months, operating cash flow was -132.2M and capital expenditures -1.25M, giving a free cash flow of -133.45M.
| Operating Cash Flow | -132.2M |
| Capital Expenditures | -1.25M |
| Free Cash Flow | -133.45M |
| FCF Per Share | -1.62 |
Margins
Gross margin is 49.72%, with operating and profit margins of -3317.79% and -3223.34%.
| Gross Margin | 49.72% |
| Operating Margin | -3317.79% |
| Pretax Margin | -3223.34% |
| Profit Margin | -3223.34% |
| EBITDA Margin | -3267.51% |
| EBIT Margin | -3317.79% |
| FCF Margin | -3021.37% |
Dividends & Yields
NGM does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Payout Ratio | n/a |
| Earnings Yield | -200.91% |
| FCF Yield | -188.32% |
Analyst Forecast
Currently there are no analyst rating for NGM.
| Price Target | n/a |
| Price Target Difference | n/a |
| Analyst Consensus | n/a |
| Analyst Count | n/a |
Scores
| Altman Z-Score | -4.17 |
| Piotroski F-Score | 2 |